Skip to Main content Skip to Navigation
Journal articles

Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease

Abstract : Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, the causative agent of COVID-19, now represents the sixth Public Health Emergency of International Concern (PHEIC)—as declared by the World Health Organization (WHO) since 2009. Considering that SARS-CoV-2 is mainly transmitted via the mucosal route, a therapy administered by this same route may represent a desirable approach to fight SARS-CoV-2 infection. It is now widely accepted that genetically modified microorganisms, including probiotics, represent attractive vehicles for oral or nasal mucosal delivery of therapeutic molecules. Previous studies have shown that the mucosal administration of therapeutic molecules is able to induce an immune response mediated by specific serum IgG and mucosal IgA antibodies along with mucosal cell-mediated immune responses, which effectively concur to neutralize and eradicate infections. Therefore, advances in the modulation of mucosal immune responses, and in particular the use of probiotics as live delivery vectors, may encourage prospective studies to assess the effectiveness of genetically modified probiotics for SARS-CoV-2 infection. Emerging trends in the ever-progressing field of vaccine development re-emphasize the contribution of adjuvants, along with optimization of codon usage (when designing a synthetic gene), expression level, and inoculation dose to elicit specific and potent protective immune responses. In this review, we will highlight the existing pre-clinical and clinical information on the use of genetically modified microorganisms in control strategies against respiratory and non-respiratory viruses. In addition, we will discuss some controversial aspects of the use of genetically modified probiotics in modulating the cross-talk between mucosal delivery of therapeutics and immune system modulation.
Document type :
Journal articles
Complete list of metadata

https://hal.inrae.fr/hal-03320040
Contributor : Camille Serva <>
Submitted on : Friday, August 13, 2021 - 4:36:24 PM
Last modification on : Wednesday, August 18, 2021 - 3:26:36 AM

File

2021_Sedigheh Taghinezhad_vacc...
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Sedigheh Taghinezhad-S, Amir Mohseni, Luis Bermúdez-Humarán, Vincenzo Casolaro, Naima Cortes-Perez, et al.. Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease. Vaccines, MDPI, 2021, 9 (5), pp.1-21. ⟨10.3390/vaccines9050466⟩. ⟨hal-03320040⟩

Share

Metrics

Record views

66

Files downloads

23